Results 121 to 130 of about 21,353 (254)

In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorthiazide, among Palestinian hypertensive patients

Therapeutics and Clinical Risk Management, 2016
Abdel Naser Zaid,1 Masshour Ghanem,2 Dua’a Shweiki,1 Hala Shtewi,1 Raja’ Shaheen,1 Sondos Al Helaly,1 Zeina Khayyat,1 Rowa’a Al Ramahi,1 Sa’ed H Zyoud1 1Department of Pharmacy, Faculty of Medicine & Health Sciences, An-Najah ...
Zaid AN, Ghanem M, Shweiki D, Shtewi H, Shaheen R, Al Helaly S, Khayyat Z, Al Ramahi R, Zyoud SH   +8 more
doaj  

Serious bacterial infections in patients with rheumatoid arthritis under anti‐TNF‐α therapy [PDF]

, 2017
Objective. With rising numbers of anti‐tumour necrosis factor α (TNF‐α) treatments for rheumatoid arthritis (RA), Crohn's disease and other conditions, physicians unaware of potential pitfalls are increasingly likely to encounter associated severe ...
Hasler, P., Kroesen, S., Tyndall, A., Widmer, A. F.   +3 more
core  

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States

Drug, Healthcare and Patient Safety, 2015
Michele Jara, Thomas Aquilina, Peter Aupperle, Adrian L Rabinowicz Acorda Therapeutics, Inc., Ardsley, NY, USA Background: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US ...
Jara M, Aquilina T, Aupperle P, Rabinowicz AL   +3 more
doaj  

Postmarketing surveillance study of benazepril in chinese patients with hypertension: An open-label, experimental, epidemiologic study

, 2004
Jun Lü, Liming Lee, Weihua Cao, Siyan Zhan, Guoying Zhu, Liqiang Dai, Yonghua Hu   +6 more
openalex   +2 more sources

The Ethics of Postmarketing Observational Studies of Drug Safety Under Section 505(o)(3) of the Food, Drug, and Cosmetic Act [PDF]

, 2012
Barbara J. Evans
openalex   +1 more source

Direct‐acting oral anticoagulants and alopecia: The valuable support of postmarketing data

, 2020
Giulia Bonaldo, Alberto Vaccheri, Domenico Motola   +2 more
openalex   +2 more sources

Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. [PDF]

, 1992
D G Colin‐Jones, M. J. S. Langman, D. H. Lawson, RF Logan, K. R. Paterson, M P Vessey   +5 more
openalex   +1 more source

Postmarketing Follow-Up of a Digital Home Exercise Program for Back, Hip, and Knee Pain: Retrospective Observational Study With a Time-Series and Matched-Pair Analysis (Preprint)

, 2022
Gisbert Wilhelm Teepe, Tobias Kowatsch, Felix Patricius Hans, Leo Benning   +3 more
openalex   +1 more source

Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database

BMC Gastroenterology
Background The incidence of pediatric inflammatory bowel disease (IBD) significantly increased recently. Infliximab (IFX) and adalimumab (ADA), both TNF-α inhibitors, are the only FDA-approved treatments for pediatric IBD. Due to the unique physiological
Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao   +7 more
doaj   +1 more source

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. [PDF]

, 2019
Proton-pump inhibitors, PPIs, are considered effective therapy for stomach acid suppression due to their irreversible inhibition of the hydrogen/potassium pump in the gastric parietal cells. They are widely prescribed and are considered safe for over-the-
Abagyan, Ruben, Alpatty, Sama, Atayee, Rabia S, Lee, Kelly C, Makunts, Tigran   +4 more
core   +1 more source